News
INRLF
2.800
NaN%
--
Emergent BioSolutions: Down 40%+ From Recent Highs And Likely More To Come
Seeking Alpha · 1d ago
Weekly Report: what happened at INRLF last week (0601-0605)?
Weekly Report · 2d ago
Weekly Report: what happened at INRLF last week (0525-0529)?
Weekly Report · 06/01 09:56
Weekly Report: what happened at INRLF last week (0518-0522)?
Weekly Report · 05/25 09:58
Weekly Report: what happened at INRLF last week (0511-0515)?
Weekly Report · 05/18 09:58
Valneva GAAP EPS of -€0.18, revenue of €30.9M; updates FY26 outlook
Seeking Alpha · 05/13 05:15
Weekly Report: what happened at INRLF last week (0504-0508)?
Weekly Report · 05/11 09:56
Weekly Report: what happened at INRLF last week (0427-0501)?
Weekly Report · 05/04 09:55
Weekly Report: what happened at INRLF last week (0420-0424)?
Weekly Report · 04/27 09:56
Weekly Report: what happened at INRLF last week (0413-0417)?
Weekly Report · 04/20 09:54
Weekly Report: what happened at INRLF last week (0406-0410)?
Weekly Report · 04/13 09:57
Weekly Report: what happened at INRLF last week (0330-0403)?
Weekly Report · 04/06 09:56
Weekly Report: what happened at INRLF last week (0323-0327)?
Weekly Report · 03/30 09:57
Pfizer, Valneva SE report phase 3 results for Lyme vaccine candidate
Seeking Alpha · 03/23 11:51
Weekly Report: what happened at INRLF last week (0316-0320)?
Weekly Report · 03/23 09:54
Valneva reports FY results; gives FY26 outlook
Seeking Alpha · 03/18 06:24
Weekly Report: what happened at INRLF last week (0309-0313)?
Weekly Report · 03/16 09:54
Weekly Report: what happened at INRLF last week (0302-0306)?
Weekly Report · 03/09 09:55
Weekly Report: what happened at INRLF last week (0223-0227)?
Weekly Report · 03/02 09:54
Weekly Report: what happened at INRLF last week (0216-0220)?
Weekly Report · 02/23 09:54
More
Webull provides a variety of real-time INRLF stock news. You can receive the latest news about Valneva Se through multiple platforms. This information may help you make smarter investment decisions.
About INRLF
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.